KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Gains from Investment Securities (2018 - 2020)

Historic Gains from Investment Securities for Esperion Therapeutics (ESPR) over the last 3 years, with Q2 2020 value amounting to $4.6 million.

  • Esperion Therapeutics' Gains from Investment Securities fell 1399.52% to $4.6 million in Q2 2020 from the same period last year, while for Jun 2020 it was $4.6 million, marking a year-over-year decrease of 1399.52%. This contributed to the annual value of $4.7 million for FY2019, which is 1179.91% down from last year.
  • Esperion Therapeutics' Gains from Investment Securities amounted to $4.6 million in Q2 2020, which was down 1399.52% from $4.8 million recorded in Q1 2020.
  • In the past 5 years, Esperion Therapeutics' Gains from Investment Securities ranged from a high of $5.3 million in Q2 2019 and a low of $4.2 million during Q1 2018
  • Moreover, its 3-year median value for Gains from Investment Securities was $4.8 million (2019), whereas its average is $4.8 million.
  • As far as peak fluctuations go, Esperion Therapeutics' Gains from Investment Securities soared by 2542.02% in 2019, and later crashed by 1399.52% in 2020.
  • Over the past 3 years, Esperion Therapeutics' Gains from Investment Securities (Quarter) stood at $5.3 million in 2018, then decreased by 11.8% to $4.7 million in 2019, then fell by 2.14% to $4.6 million in 2020.
  • Its Gains from Investment Securities stands at $4.6 million for Q2 2020, versus $4.8 million for Q1 2020 and $4.7 million for Q4 2019.